VISCHER advises RELIEF on CHF 5m private placement

RELIEF THERAPEUTICS Holding has entered into has entered into a definitive agreement for the sale and purchase in a private placement of 1.5m Relief shares and warrants to purchase up to 1.5m Relief shares.

The warrants will have an exercise price of CHF 3.40 per share, will be immediately exercisable upon issuance, and will expire five years from the date of issuance.The aggregate gross proceeds from the private placement were approximately CHF 5m. The transaction closed on 23 June 2023.

RELIEF is a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases.

VISCHER advised Relief regarding the Swiss legal aspects of this transaction. The team led by partner Robert Bernet (pictured) comprised Peter Kühn (counsel, both corporate/m&a) and Christian Schneiter (senior associate, banking & finance).

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.